|

Hybrid Endoscopic Hemithyroidectomy and Targeted Ablation for Bilateral Papillary Thyroid Carcinoma

RECRUITINGN/ASponsored by Fujian Medical University
Actively Recruiting
PhaseN/A
SponsorFujian Medical University
Started2018-06-01
Est. completion2026-06-30
Eligibility
Age18 Years – 65 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07033572

Summary

This study evaluates a thyroid-function-preserving alternative to routine total thyroidectomy for bilateral papillary thyroid carcinoma (PTC). Eligible adults undergo remote-access gas-less axillo-breast endoscopic hemithyroidectomy with level VI dissection on the dominant side, followed by ultrasound-guided radiofrequency ablation (RFA) of a ≤7 mm contralateral focus during the same anesthesia. Outcomes include structural-recurrence-free survival, endocrine-function preservation, safety, and quality of life over 24 months.

Eligibility

Age: 18 Years – 65 YearsHealthy volunteers accepted
Inclusion Criteria:

* Age 18-65 years.
* Dominant-side PTC ≤1.5 cm suitable for endoscopic resection.
* Contralateral nodule ≤7 mm located ≥2 mm from posterior capsule.
* No radiologic lymph-node metastasis on contralateral side.
* Written informed consent.

Exclusion Criteria:

* Extrathyroidal extension, gross nodal or distant metastasis.
* Prior neck surgery, prior RFA/ethanol injection, or neck irradiation.
* Pregnancy or lactation.
* Serious comorbidities precluding anesthesia or follow-up.

Conditions3

CancerCarcinoma, PapillaryThyroid Neoplasms

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.